Glyoxal monoxime, 2-(4-fluorophenyl)-

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Glyoxal monoxime, 2-(4-fluorophenyl)-
• 英文别名: (2E)-1-(4-fluorophenyl)-2-hydroxyiminoethanone
• 化学式: C₈H₆FNO₂
• 分子量: 167.14
• InChiKey: FTSKJDZBOFFAKJ-BJMVGYQFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS
  申请人：Herdewijn Piet André Maurits Maria

  公开号：US20100305117A1

  公开（公告）日：2010-12-02

  The invention provides 4,6-di- and 2,4,6-tri-substituted pteridine derivatives with a specific substitution pattern which exhibit a significant and selective activity against certain types of viral infections, in particular selectively inhibit replication of Flaviridae such as the hepatitis C virus, and are useful for the prevention and treatment of such viral infections.

  该发明提供了具有特定取代模式的4,6-二取代和2,4,6-三取代的喹啉衍生物，对某些类型的病毒感染表现出显著和选择性的活性，特别是选择性地抑制黄热病病毒等黄病毒科的复制，并且对预防和治疗此类病毒感染有用。
• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson Howard John

  公开号：US20070225285A1

  公开（公告）日：2007-09-27

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一些化合物和包含这些化合物的药物组合物，这些化合物可以调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这些FLAP调节剂的方法，单独或与其他化合物组合使用，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或症状。
• Pteridine derivatives useful for making pharmaceutical compositions
  申请人：Waer Jozef Albert Mark

  公开号：US20070032477A1

  公开（公告）日：2007-02-08

  This invention relates to a group of substituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydro-derivatives, and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These derivatives are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system, TNF-α related disorders, viral diseases, inflammatory bowel diseases and cell proliferative disorders.

  本发明涉及一类取代的喹噁啉衍生物，其药学上可接受的盐、N-氧化物、溶剂合物、二氢和四氢衍生物以及对映体，具有出乎意料的理想药理特性，尤其是高活性的免疫抑制剂，因此在移植排斥和/或某些炎症性疾病的治疗中非常有用。这些衍生物还可用于预防或治疗心血管疾病、过敏性疾病、中枢神经系统疾病、TNF-α相关疾病、病毒性疾病、炎症性肠病和细胞增殖性疾病。
• 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
  申请人：Hutchinson John Howard

  公开号：US20110034514A1

  公开（公告）日：2011-02-10

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了含有这些化合物的药物组合物，这些化合物可以调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这些FLAP调节剂的方法，单独或与其他化合物组合，用于治疗呼吸系统、心血管系统和其他依赖或介导白三烯的疾病或病症。
• HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY
  申请人：4 AZA Bioscience nv

  公开号：EP1673092A1

  公开（公告）日：2006-06-28